SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SYRE SPYRE THERAPEUTICS INC

交易中 06-16 15:13:35 EDT

83.66

+0.08

+0.10%

最高84.59	最低81.70	成交量67.64万
今开83.54	昨收83.58	日振幅3.46%
总市值72.65亿	流通市值60.70亿	总股本8,684万
成交额5,608万	换手率0.93%	流通股本7,255万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":83.66,"timestamp":1781637213468,"preClose":83.58,"halted":0,"volume":676378,"delay":0,"changeRate":0.0009571667863124946,"floatShares":72553500,"shares":86841253,"eps":-2.166825,"marketStatus":"交易中","change":0.08,"latestTime":"06-16 15:13:35 EDT","open":83.54,"high":84.59,"low":81.7,"amount":56078130.677612,"amplitude":0.034578,"askPrice":83.84,"askSize":188,"bidPrice":83.6,"bidSize":22,"shortable":3,"etf":0,"ttmEps":-2.166825,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781640000000},"marketStatusCode":2,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":83.58,"preHourTrading":{"tag":"盘前","latestPrice":83.55,"preClose":83.58,"latestTime":"09:15 EDT","volume":129,"amount":10653.732546,"timestamp":1781615716310,"change":-0.03,"changeRate":-0.000359,"amplitude":0.041199},"postHourTrading":{"tag":"盘后","latestPrice":83,"preClose":83.58,"latestTime":"19:15 EDT","volume":33924,"amount":2835039.2886,"timestamp":1781565321762,"change":-0.58,"changeRate":-0.006939,"amplitude":0.011965},"volumeRatio":0.643537,"impliedVol":0.7311,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/SYRE","defaultTab":"news","newsList":[{"id":"1132100150","title":"Spyre Therapeutics：二十名受试者出现治疗引发不良事件；两例严重，均与药物无关","url":"https://stock-news.laohu8.com/highlight/detail?id=1132100150","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132100150?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:03","pubTimestamp":1781525007,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公布了一项临床试验的更新数据，显示有二十名受试者出现了治疗引发的不良事件。其中，两例被评估为严重级别，但经过分析，这些严重事件均被判定与试验药物本身无关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107639416","title":"SPYRE THERAPEUTICS：Spy002在第12周实现33%临床缓解与42%内镜改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1107639416","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107639416?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:02","pubTimestamp":1781524958,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS公司宣布，其候选药物Spy002在治疗第12周时取得了令人鼓舞的临床数据。\n结果显示，接受治疗的患者中有33%达到了临床缓解的标准。同时，内镜检查评估显示，42%的患者实现了内镜下病情的显著改善。\n这些中期数据为该药物的后续开发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178318875","title":"Spyre公布其潜在同类最佳药物Spy002（抗TL1A）在Skyline试验中治疗中重度溃疡性结肠炎患者的A部分诱导结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1178318875","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178318875?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:01","pubTimestamp":1781524915,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司宣布，其候选药物Spy002（一种抗TL1A疗法）在针对中重度溃疡性结肠炎患者的Skyline试验中，取得了A部分的诱导期结果。数据显示，该药物展现出成为同类最佳疗法的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196395365","title":"Spyre Therapeutics宣布Skyway篮子试验完成患者入组，评估Spy072（抗TL1A）治疗RA、PsA及AxSpa","url":"https://stock-news.laohu8.com/highlight/detail?id=1196395365","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196395365?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:08","pubTimestamp":1780488531,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc (SPYRE THERAPEUTICS INC) 已宣布，其针对Spy072（一种抗TL1A疗法）的Skyway篮子试验患者入组工作现已完成。该试验旨在评估该疗法对类风湿关节炎（RA）、银屑病关节炎（PsA）以及中轴型脊柱关节炎（AxSpa）患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146674317","title":"Spyre Therapeutics重申预期：类风湿关节炎试验数据将于2026年第三季度揭晓，银屑病关节炎与中轴型脊柱关节炎数据预计第四季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146674317","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146674317?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:06","pubTimestamp":1780488378,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司再次确认其关键临床试验的预期数据公布时间线。针对类风湿关节炎（Ra）的研究数据，预计将在2026年第三季度获得并公布。此外，关于银屑病关节炎（Psa）以及中轴型脊柱关节炎（Axspa）的试验数据，公司则预计将在2026年第四季度陆续揭晓。\n这一时间表的重申，为关注该公司研发管线的投资者提供了明确的关键节点。不同适应症的数据分阶段出炉，或将影响市场对公司未来前景的评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162858091","title":"Spyre Therapeutics：Skyway与Skyline试验齐头并进，计划中的“2026年六项”二期数据读出已就绪并按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1162858091","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162858091?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:06","pubTimestamp":1780488377,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布，其Skyway与Skyline临床试验项目进展顺利，原定于2026年完成的六项二期研究数据读出已具备条件，并正按既定时间表稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179769071","title":"Spyre Therapeutics重大协议触发条款：2028年6月1日后初始领域外给药限制将解除","url":"https://stock-news.laohu8.com/highlight/detail?id=1179769071","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179769071?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:06","pubTimestamp":1780344382,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）的一份文件披露，Spyre Therapeutics Inc.已达成一项重大协议。该协议包含一项关键条款：自2028年6月1日起，针对初始领域之外的给药限制将被解除。这一变动标志着公司研发管线在特定时间点后将获得更广泛的开发自由度，可能为后续临床试验的拓展铺平道路。文件显示，此次协议触发的限制解除是预先设定的条件之一，符合公司长远的战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150438791","title":"Spyre Therapeutics 与 Paragon Therapeutics 签署许可协议首次修订案","url":"https://stock-news.laohu8.com/highlight/detail?id=1150438791","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150438791?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:05","pubTimestamp":1780344311,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc (股票代码: SYRE) 于2026年5月29日，与Paragon Therapeutics就其许可协议签署了第一份修订案。该信息已通过美国证券交易委员会（SEC）文件正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138781160","title":"Spyre Therapeutics公布2026年一季度财务数据：现金及等价物达7.415亿美元 资金可支撑运营至2029年下半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1138781160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138781160?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:11","pubTimestamp":1777983099,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics Inc最新财务数据显示，截至2026年3月31日，公司持有的现金、现金等价物及有价证券总额达到7.415亿美元。这一资金规模预计能为公司持续运营提供充足保障，资金跑道将延续至2029年下半年。\n值得注意的是，强劲的现金储备为Spyre Therapeutics推进其创新疗法研发提供了坚实后盾。在当前生物科技领域融资环境充满挑战的背景下，该公司依然保持着稳健的财务态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120556014","title":"异动解读 | Spyre Therapeutics获强力买入评级，盘前大涨6.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120556014","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120556014?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:31","pubTimestamp":1776173485,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc（SYRE）今日盘前股价大涨6.99%，引起了市场的关注。消息面上，Raymond James分析师马丁・奥斯特首次覆盖Spyre Therapeutics，并给予其“强力买入”评级，目标价设定为80美元。该目标价显著高于公司股票周一63.27美元的收盘价，这向市场传递了积极的信号，增强了投资者对公司未来股价表现的信心，从而推动了股价在盘前交易中上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627469264","title":"【券商聚焦】华尔街顶尖分析师调整闪迪等多家企业评级展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2627469264","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627469264?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:12","pubTimestamp":1776168740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华尔街头部分析师近期陆续更新多家热门上市公司的投资评级与目标价：Evercore ISI分析师阿米特达里亚尼首次覆盖闪迪 ，给予其跑赢大盘评级，设定目标价 1200 美元。摩根士丹利分析师罗纳德坎德姆首次覆盖Janus Living，给出增持评级，目标价定为 28 美元。Evercore ISI 分析师彼得莱文首次覆盖边缘云服务商Fastly，评级为跑赢大盘，目标价 32 美元，该股周一收盘价 24.37 美元。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZWQyMzQ4MWViNTBlNjYyZWIyNzg3MGMyMTYyODU5MDY5NTc1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZWQyMzQ4MWViNTBlNjYyZWIyNzg3MGMyMTYyODU5MDY5NTc1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","BK4225","BK4554","BK4120","SNXX","SNDK","SYRE","LU0054578231.USD","BK4608","BK4139","BK4007","FSLY","BK4588","BK4613","LU0963586101.USD","JAN","BK4116","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104189294","title":"Spyre Therapeutics公司宣布暂停并终止ATM发行招股说明书 2026年4月13日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1104189294","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104189294?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:31","pubTimestamp":1776112280,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会的文件显示，生物制药公司Spyre Therapeutics Inc已决定暂停并终止其在场内发行计划相关的招股说明书。该决定将于2026年4月13日正式生效。这意味着Spyre Therapeutics公司将不再通过ATM发行方式出售普通股。ATM发行是一种灵活的融资方式，允许上市公司在需要时通过经纪商在公开市场上逐步出售股票。暂停和终止ATM招股说明书的举措，通常意味着公司短期内不会通过该渠道进行股权融资。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627458246","title":"Spyre盘前股价上涨23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458246","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627458246?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:47","pubTimestamp":1776080820,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，Spyre盘前股价上涨23%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-13/doc-inhukeex9689769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-13/doc-inhukeex9689769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2360106780.USD","BK4539","BK4608","LU2063271972.USD","BK4551","LU0353189680.USD","AIYY","LU0353189763.USD","LU1852331112.SGD","BK4528","LU0056508442.USD","APPX","BK4023","LU2087625088.SGD","BK4587","LU1861215975.USD","LU0097036916.USD","LU1861220033.SGD","IE00BZ9MQY76.HKD","IE00B19Z9Z06.USD","BK4585","LU2290526834.HKD","BK4588","BK4613","LU2250418816.HKD","IE00B894F039.SGD","SYRE","LU2360107168.USD","BK4543","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188201235","title":"SPYRE THERAPEUTICS INC股价盘前飙升23% 公司宣布炎症性肠病药物中期研究显示疾病活动度降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1188201235","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188201235?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:46","pubTimestamp":1776080778,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS INC股价在盘前交易中大幅上涨23%，此前该公司宣布其针对炎症性肠病的药物在一项中期研究中显示出能够显著降低疾病活动度。\n这一积极的研究结果提振了投资者信心，推动该公司股价在开盘前即迎来强劲涨势。该药物在临床试验中达到主要终点，为患有此类慢性肠道疾病的患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191160307","title":"Spyre公布Skyline试验中重度溃疡性结肠患者Spy001 Part a诱导期潜在最佳疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1191160307","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191160307?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:09","pubTimestamp":1776078591,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics公布了其Skyline临床试验中针对中重度溃疡性结肠炎患者的Spy001 Part a诱导期研究结果，数据显示该疗法可能具备同类最优潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197836690","title":"Spyre Therapeutics：诱导治疗期间六名受试者出现治疗突发不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197836690","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197836690?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078043,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司在诱导治疗阶段报告了六例治疗相关不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175357309","title":"Spyre Therapeutics药物Spy001达成主要终点：RHI评分显著降低9.2分，统计学差异凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=1175357309","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175357309?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078031,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc宣布，其候选药物Spy001在临床试验中成功达成主要研究终点。数据显示，该药物使RHI评分出现具有统计学意义的显著下降，降幅达到9.2分。这一积极结果标志着项目取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152663853","title":"Spyre Therapeutics次要终点数据亮眼：改良Mayo评分临床缓解率达40%，内镜改善率51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152663853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152663853?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078015,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司最新研究数据显示，其次要疗效终点取得显著成果。根据改良Mayo评分标准，患者临床缓解率达到40%，同时内镜下黏膜改善率表现更为突出，达到51%的水平。\n该数据反映了候选疗法在炎症性肠病治疗领域的潜在价值，两项关键指标共同印证了治疗方案的临床有效性。值得注意的是，内镜改善率超过临床缓解率11个百分点，提示该疗法可能对黏膜愈合具有特别优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129097336","title":"Spyre Therapeutics公布Spy001二期Skyline试验A部分12周诱导期积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1129097336","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129097336?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078011,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics近日宣布，其在研药物Spy001于二期临床试验Skyline的A部分取得了积极的12周诱导期数据。这项进展为后续研究奠定了良好基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148597267","title":"Spyre Therapeutics宣布Skyway类风湿性关节炎亚组研究顶线结果预期提前至2026年第三季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1148597267","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148597267?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664501,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics最新公告显示，其针对类风湿性关节炎的Skyway研究项目亚组分析顶线结果揭晓时间将较原计划提前。该关键数据发布节点现已调整为2026年第三季度。\n此次时间表优化源于临床研究进程的显著提速，预示着公司在该疾病领域的研发效率获得实质性突破。作为自身免疫疾病治疗领域的重要进展，这项亚组研究结果的提前披露将为药物疗效评估提供更早的决策依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyre.com","stockEarnings":[{"period":"1week","weight":0.1608},{"period":"1month","weight":0.1156},{"period":"3month","weight":0.9017},{"period":"6month","weight":1.5281},{"period":"1year","weight":3.834},{"period":"ytd","weight":1.5513}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法，创造下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.035303},{"month":2,"riseRate":0.5,"avgChangeRate":0.028912},{"month":3,"riseRate":0.5,"avgChangeRate":0.022238},{"month":4,"riseRate":0.2,"avgChangeRate":-0.009955},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.054533},{"month":6,"riseRate":0.454545,"avgChangeRate":0.120807},{"month":7,"riseRate":0.4,"avgChangeRate":-0.002229},{"month":8,"riseRate":0.8,"avgChangeRate":0.108946},{"month":9,"riseRate":0.6,"avgChangeRate":0.016514},{"month":10,"riseRate":0.4,"avgChangeRate":0.109394},{"month":11,"riseRate":0.4,"avgChangeRate":0.005048},{"month":12,"riseRate":0.4,"avgChangeRate":-0.019416}],"exchange":"NASDAQ","name":"SPYRE THERAPEUTICS INC","nameEN":"SPYRE THERAPEUTICS INC"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SPYRE THERAPEUTICS INC,SYRE,SPYRE THERAPEUTICS INC股票,SPYRE THERAPEUTICS INC股票老虎,SPYRE THERAPEUTICS INC股票老虎国际,SPYRE THERAPEUTICS INC行情,SPYRE THERAPEUTICS INC股票行情,SPYRE THERAPEUTICS INC股价,SPYRE THERAPEUTICS INC股市,SPYRE THERAPEUTICS INC股票价格,SPYRE THERAPEUTICS INC股票交易,SPYRE THERAPEUTICS INC股票购买,SPYRE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}